{
    "clinical_study": {
        "@rank": "144637", 
        "arm_group": [
            {
                "arm_group_label": "sorafenib", 
                "arm_group_type": "Experimental", 
                "description": "sorafenib 400mg, oral, twice a day until disease progression defined by RECIST."
            }, 
            {
                "arm_group_label": "Best Supportive Care", 
                "arm_group_type": "Active Comparator", 
                "description": "treatment mainly on nutrition and symptoms control"
            }
        ], 
        "brief_summary": {
            "textblock": "Due to the HBV and HCV infection, about 55% hepatocellular carcinoma patients happened in\n      China. Among them, only 10% patients can be diagnosed in early stage. Sorafenib increased\n      PFS and OS in advanced hepatocellular carcinoma patients with liver function of Child-Pugh\n      class A patients, but the result for Child-Pugh class B patients is unclear."
        }, 
        "brief_title": "Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Liver Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Liver Neoplasms", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  pathological or cytological confirmed advanced hepatocellular carcinoma\n\n          -  18 years to 80 years\n\n          -  liver function Child-Pugh class B\n\n          -  BCLC stage B or C\n\n          -  estimated life time 2 months or longer\n\n        Exclusion Criteria:\n\n          -  previous target therapy\n\n          -  allergy to Sorafenib\n\n          -  Uncontrolled Bleeding or diarrhea\n\n          -  eligible for locoregional treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01932385", 
            "org_study_id": "QCH20130823"
        }, 
        "intervention": [
            {
                "arm_group_label": "sorafenib", 
                "intervention_name": "Sorafenib", 
                "intervention_type": "Drug", 
                "other_name": "Nexavar"
            }, 
            {
                "arm_group_label": [
                    "sorafenib", 
                    "Best Supportive Care"
                ], 
                "intervention_name": "Best Supportive Care", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sorafenib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Sorafenib", 
            "Hepatocellular carcinoma", 
            "Best supportive care", 
            "Survival"
        ], 
        "lastchanged_date": "September 5, 2013", 
        "location": {
            "contact": {
                "last_name": "youxin ji, M.D.", 
                "phone": "8653268665078"
            }, 
            "facility": {
                "address": {
                    "city": "Qingdao", 
                    "country": "China", 
                    "state": "Shandong", 
                    "zip": "266042"
                }, 
                "name": "Qingdao Central Hospital, Qingdao Cancer Hospital"
            }, 
            "investigator": {
                "last_name": "youxin ji, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 2 Study of Sorafenib in the Management of Liver Function Impaired Advanced Hepatocellular Carcinoma", 
        "overall_official": {
            "affiliation": "Qingdao Health Bereau", 
            "last_name": "ketao lan, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "progression free survival and overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "From date of randomization until the date of first documented progression or date of death from any cause up to 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01932385"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Qingdao Central Hospital", 
            "investigator_full_name": "Youxin Ji", 
            "investigator_title": "Chief, Department of Oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "response rate", 
            "safety_issue": "Yes", 
            "time_frame": "every 4 weeks till progression, total up to 12 months"
        }, 
        "source": "Qingdao Central Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Qingdao Central Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}